Overview

Safety and Effects on Responses to Stress and Pain of Natural Medical Marijuana Products

Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This proposal aims to systematically examine the safety and pharmacokinetic/pharmacodynamic profile and the physiologic, neuroendocrine and behavioral stress and pain responses to acute single doses and repeated dosing of oral tablet formulation of natural Cannabidiol (CBD) alone and in combination with Tetrahydrocannabinol and matched Placebo (PLA).
Phase:
Phase 1
Details
Lead Sponsor:
Yale University
Collaborator:
Connecticut Pharmaceutical Solutions
Treatments:
Dronabinol
Epidiolex